Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dammarane aglycon compound and application thereof

A technology for dammarane aglycone and complex, which is applied to the dammarane aglycone complex and its application field, can solve the problems such as the prevention and protection of myelosuppression that have not been reported, and achieves an increase in peripheral blood levels and colonies. Quantity, clear effect of protective effect

Inactive Publication Date: 2011-07-20
TIANMA PHARMA GROUP +1
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there have been a large number of literature reports so far that the total saponins, subsides and aglycones from ginseng stems and leaves have significant antitumor activity, the aglycon complexes after alkali hydrolysis of total saponins from ginseng stems and leaves have no effect on various radiotherapy and chemotherapy. The preventive and protective effects of the resulting myelosuppression have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dammarane aglycon compound and application thereof
  • Dammarane aglycon compound and application thereof
  • Dammarane aglycon compound and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Effects of dammarane aglycon complex on the colony number of hematopoietic progenitor cells in myelosuppressed mice

[0022] Cyclophosphamide 200mg / kg was used in the experiment, and mice were injected intraperitoneally once to establish a model. Three days after the model was established, bone marrow cells were collected for colony culture, and different concentrations of dammarane aglycon complexes were added to the culture system. The experimental results are shown in Table 1. Among them, the mice in the model group were not administered externally with the dammarane aglycon complex, and the mice in the experimental group were administered externally with different concentrations of the dammarane aglycon complex.

[0023] Table 1 The effect of dammarane aglycon complex on the number of hematopoietic progenitor cell colonies in myelosuppressed mice ( n=3)

[0024]

[0025] Note: * means P<0.05; ** means P<0.01, compared with the model group.

[0026] Experiment...

Embodiment 2

[0028] Effects of Oral Administration of Dammarane Aglycone Complex on Peripheral Blood of Mice with Myelosuppression Induced by Cyclophosphamide

[0029] Experimental settings Control group, model group, low-dose group (oral administration of dammarane aglycon complex 37.5mg / kg), medium-dose group (oral administration of dammarane aglycon complex 75mg / kg) and high-dose group (Orally administered dammarane aglycon complex 150 mg / kg group), and the positive drug group. Except for the control group, all other groups were intraperitoneally injected with cyclophosphamide (CTX) 200 mg / kg to establish models, and half an hour after the injection, 0.2 ml / 10 g of dammarane aglycone complex of the corresponding concentration was intragastrically administered every day. The G-CSF test solution, 0.1ml / 10g, was injected subcutaneously in the control group and 0.2ml / 10g of distilled water in the control group and the model group for 5 consecutive days. The experimental results are shown i...

Embodiment 3

[0039] Effects of dammarane aglycon complex on hematopoietic progenitor cells in mice with myelosuppression induced by cyclophosphamide

[0040] On the day of the experiment, the mice were intraperitoneally injected with cyclophosphamide to establish a model, and the administration group was given a small dose (37.5 mg / kg), a medium dose (75 mg / kg) and a large dose (150 mg / kg) of dammarane aglycone complex by intragastric administration immediately after the model was established. / kg), the normal group and the model group were given the same volume of distilled water, the administration volume was 0.2ml / 10g, and the administration was continued for 10 days. The results are shown in Table 3.

[0041] Table 3 Effects of dammarane aglycon complex on hematopoietic progenitor cells in mice with bone marrow suppression induced by cyclophosphamide ( n=6)

[0042]

[0043] Note: ## means p<0.01, compared with the normal group; * means p<0.05, ** means p<0.01, compared with the m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a dammarane aglycon compound and application thereof, in particular to application of oral administration and injection preparations which are prepared by a single dammarane aglycon compound prepared by basic hydrolysis by utilizing the particular patent technology of the Pegasus Pharmaceuticals Group of Canada by adopting Asian ginseng stem and leave saponin or prepared in the way that the dammarane aglycon compound is matched with other medically permissive auxiliary materials in prevention and treatment on bone marrow suppression caused by different chemotherapy and radiotherapy.

Description

technical field [0001] The present invention relates to a dammarane aglycon compound and its application, specifically, a dammarane prepared by using the total saponins of Asian ginseng stems and leaves through alkali hydrolysis by using the unique patented technology of Canadian Tianma Pharmaceutical Group The aglycon complex (Panagin DS-1226) is made into oral and injection dosage forms alone or in combination with other pharmaceutically acceptable excipients, and is used for the prevention and treatment of bone marrow suppression caused by various chemotherapy and radiotherapy. Background technique [0002] The dammarane aglycon complex of the present invention is aglycon complex prepared by using the unique patented technology of Canadian Tianma Pharmaceutical Group and using the total saponins of Asian ginseng stems and leaves through alkaline hydrolysis. Although there have been a large number of literature reports so far that the total saponins, subsides and aglycones...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/575A61P7/00A61P7/06
Inventor 黄冬刘新民王天山祁东风杨艳艳许秋霞
Owner TIANMA PHARMA GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com